What is the 13F Pro Quality Score for VTRS?

13F Pro ranks Viatris Inc (VTRS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VTRS's current score at https://13fpro.ai/research/VTRS (free sign-up required for the full ranking).

Which hedge funds own the most VTRS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VTRS include BlackRock,, DAVIS SELECTED ADVISERS, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VTRS as soon as new 13F filings post.

Where does 13F Pro source VTRS data?

All Viatris Inc fundamentals and ownership data come directly from SEC EDGAR. Viatris Inc files with the SEC under CIK 1792044. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VTRS in?

Viatris Inc (VTRS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VTRS research updated on 13F Pro?

VTRS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Viatris Inc(VTRS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1792044 VTRS stock profile & AI dashboard →

13F Pro Quality Score

47.1/100

Rank #1,613 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

21.5/100

Profitability

30.0/100

Balance Sheet

30.0/100

Earnings Quality

30.0/100

Free Cash Flow

67.1/100

Institutional Flow

92.7/100

Revenue Scale

89.9/100

Dilution Risk

51.5/100

VTRS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Viatris Inc (VTRS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VTRS at 47.1/100 on a 32-signal composite quality model, placing it at rank #1,613 of 2,879 stocks — the bottom half of the AI-ranked universe. VTRS scores in the top quartile across institutional flow (92.7), revenue scale (89.9). Areas of concern include revenue growth (21.5) and profitability (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Viatris Inc reports quarterly revenue of $3.5B, net income of $176.4M, free cash flow of $348.4M. Top institutional holders of VTRS by reported 13-F value include BlackRock,, DAVIS SELECTED ADVISERS, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. VTRS trades on the Nasdaq exchange and files with the SEC under CIK 1792044. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VTRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Viatris Inc directly from SEC EDGAR. Viatris Inc's 13F Pro composite quality score has ranged between 8 and 63 since 2021, currently 47.1 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Viatris Inc

Quirks, history, and lore behind VTRS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. pharmaceutical company · large-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the range of $15–17 billion, yet it has carried a heavy debt load since its creation — servicing that pile is basically a part-time job.
3
The History
Born in 2020 from a mega-merger of two pharma giants — one American, one Irish — creating one of the world's largest off-patent drug makers almost overnight.
4
The Secret
Its business model leans hard on generic and off-patent medicines, meaning it competes mostly on price and scale rather than blockbuster R&D breakthroughs.
5
The Lore
It inherited a massive portfolio including the EpiPen — one of the most controversial drug-pricing stories in recent U.S. history — along with brands like Lipitor and Viagra in their generic forms.
6
The Giveaway
The offspring of Mylan and Pfizer's Upjohn division, this company's very name is a mashup of "via" and "matrix" — your last hint before the ticker reveals all.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$3.5B

Net Income

Q1 2026

$176.4M

Free Cash Flow

Q1 2026

$348.4M

D/E Ratio

Q1 2026

1.11

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-3.0% YoY

$14.30BFY 2025

FY21 $17.89BFY22 $16.26BFY24 $14.74BFY25 $14.30B

Operating Income

-26467.3% YoY

$-2.66BFY 2025

FY21 $-34.0MFY22 $1.61BFY24 $10.1MFY25 $-2.66B

EPS (Diluted)

-466.0% YoY

$-3.00FY 2025

FY21 $-1.05FY22 $1.71FY24 $-0.53FY25 $-3.00

Total Assets

-10.4% YoY

$37.19BFY 2025

FY21 $54.84BFY22 $50.02BFY24 $41.50BFY25 $37.19B

Total Debt

+16.3% YoY

$16.34BFY 2025

FY21 $24.95BFY22 $20.52BFY24 $14.05BFY25 $16.34B

Op. Cash Flow

+0.6% YoY

$2.32BFY 2025

FY21 $3.02BFY22 $3.00BFY24 $2.30BFY25 $2.32B

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2019	FY 2018
Revenue	$14.30B -3.0%	$14.74B -9.4%	$16.26B -9.1%	$17.89B +55.5%	$11.50B +0.6%	$11.43B
Operating Income	$-2.66B -26467.3%	$10.1M -99.4%	$1.61B +4849.7%	$-34.0M -104.8%	$715.5M -21.0%	$905.6M
EPS (Diluted)	$-3.00 -466.0%	$-0.53 -131.0%	$1.71 +262.9%	$-1.05 -3600.0%	$0.03 -95.6%	$0.68
Total Assets	$37.19B -10.4%	$41.50B -17.0%	$50.02B -8.8%	$54.84B	$0.00	—
Total Debt	$16.34B +16.3%	$14.05B -31.6%	$20.52B -17.7%	$24.95B +75.9%	$14.18B	—
Operating Cash Flow	$2.32B +0.6%	$2.30B -23.2%	$3.00B -0.6%	$3.02B +67.3%	$1.80B -23.0%	$2.34B

AI Insight: VTRS Financial Trends

Revenue declined 8% year-over-year in Q1 2026 to $3,517M while debt increased $2.1B from Q4 2024 lows.

• Revenue dropped from $3,254M in Q1 2025 to $3,517M in Q1 2026, an 8% year-over-year increase despite quarterly volatility.

• Total debt surged from $14,048M in Q4 2024 to $16,272M in Q1 2026, a $2.2B increase.

• Operating cash flow remains volatile, ranging from $220M to $826M across recent quarters.

⚠ Operating income turned negative in Q1 2026 at -$80M after positive $179M in Q3 2025.

⚠ Operating cash flow declined to $388M in Q1 2026 from $816M in Q4 2025.

AI Insight: VTRS Ratio Trends

Viatris exhibits extreme quarterly volatility with operating margins swinging from -88.6% in Q1 2025 to 6.5% in Q2 2025.

• Operating margin collapsed to -88.6% in Q1 2025, the worst quarterly performance in the dataset.

• ROIC mirrored operating performance, plummeting to -81.3% in Q1 2025 before recovering to 5.8% in Q2 2025.

• Recent quarters show continued negative margins with Q1 2026 at -2.3% operating margin and -2.0% ROIC.

⚠ Persistent alternating pattern between positive and negative quarterly margins suggests underlying operational instability.

⚠ TTM operating margin of just 1.0% indicates sustained profitability challenges despite occasional positive quarters.

Get alerted when VTRS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Viatris Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VTRS

BlackRock, Inc.
$1.1B84,359,804 sh
DAVIS SELECTED ADVISERS
$1.1B78,211,191 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.0B74,716,631 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$728.3M53,911,237 sh
STATE STREET CORP
$705.7M52,233,699 sh
DIMENSIONAL FUND ADVISORS LP
$517.5M38,310,693 sh
Rubric Capital Management LP
$452.6M33,500,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$429.5M31,846,107 sh
Invesco Ltd.
$296.8M21,968,657 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$273.0M20,206,170 sh

Fund	Value	Shares
BlackRock, Inc.	$1.1B	84,359,804
DAVIS SELECTED ADVISERS	$1.1B	78,211,191
VANGUARD CAPITAL MANAGEMENT LLC	$1.0B	74,716,631
VANGUARD PORTFOLIO MANAGEMENT LLC	$728.3M	53,911,237
STATE STREET CORP	$705.7M	52,233,699
DIMENSIONAL FUND ADVISORS LP	$517.5M	38,310,693
Rubric Capital Management LP	$452.6M	33,500,000
GEODE CAPITAL MANAGEMENT, LLC	$429.5M	31,846,107
Invesco Ltd.	$296.8M	21,968,657
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$273.0M	20,206,170

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VTRS on your watchlist

Track score changes the day Viatris Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VTRS a good stock to buy?

13F Pro's AI-powered analysis of Viatris Inc (VTRS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VTRS are available on the VTRS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VTRS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VTRS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Viatris Inc's investment landscape.